Literature DB >> 9198155

Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.

F Van de Werf1.   

Abstract

Glycoprotein IIb/IIIa receptor antagonists are more potent platelet inhibitors than aspirin. Although important reductions in ischemic/thrombotic complications have been observed with these agents following coronary interventions, their potential value for the medical treatment of acute coronary syndromes is at present uncertain. The final results of large randomized studies in patients with acute coronary syndromes are eagerly awaited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198155

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

Authors:  Walter Ageno; Alexander G G Turpie
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

Review 2.  Role of fibrin D-dimer testing in emergency medicine.

Authors:  A Wakai; A Gleeson; D Winter
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

Review 3.  Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Authors:  K L Goa; S Noble
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 4.  Tirofiban. A review of its use in acute coronary syndromes.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  Modulation of monocyte-endothelial cell interactions by platelet microparticles.

Authors:  O P Barry; D Praticò; R C Savani; G A FitzGerald
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

6.  Arterial indications for the low molecular weight heparins.

Authors:  Walter Ageno; Menno V Huisman
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

7.  Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.

Authors:  Nadia Heramvand; Maryna Masyuk; Johanna M Muessig; Amir M Nia; Athanasios Karathanos; Amin Polzin; Marco Valgimigli; Paul A Gurbel; Udaya S Tantry; Malte Kelm; Christian Jung
Journal:  J Thromb Thrombolysis       Date:  2022-04-28       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.